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Abstract
Background: Epilepsy is genetically complex neurological disorder affecting millions of people of different age
groups varying in its type and severity. Copy number variants (CNVs) are key players in the genetic etiology of
numerous neurodevelopmental disorders and prior findings also revealed that chromosomal aberrations are more
susceptible against the pathogenesis of epilepsy. Novel technologies, such as array comparative genomic
hybridization (array-CGH), may help to uncover the pathogenic CNVs in patients with epilepsy.
Results: This study was carried out by high density whole genome array-CGH analysis with blood DNA samples
from a cohort of 22 epilepsy patients to search for CNVs associated with epilepsy. Pathogenic rearrangements
which include 6p12.1 microduplications in 5 patients covering a total region of 99.9kb and 7q32.3 microdeletions
in 3 patients covering a total region of 63.9kb were detected. Two genes BMP5 and PODXL were located in the
predicted duplicated and deleted regions respectively. Furthermore, these CNV findings were confirmed by qPCR.
Conclusion: We have described, for the first time, several novel CNVs/genes implicated in epilepsy in the Saudi
population. These findings enable us to better describe the genetic variations in epilepsy, and could provide a
foundation for understanding the critical regions of the genome which might be involved in the development of
epilepsy.
Background
Epilepsy is one of the most common neurological disorder
in humans with 1% prevalence and a lifetime incidence of
up to 3%; characterized by recurrent and unprovoked sei-
zures because of an abnormal electrical activity in central
nervous system (CNS) [1]. More than 50 distinct epilepsy
syndromes have been recognized with a broad range of
clinical features; roughly it can be divided into idiopathic
or symptomatic epilepsies. Metabolic disorders, infections,
stroke, head trauma or brain tumors may cause sympto-
matic epilepsy whereas idiopathic seizure occur mainly
because of genetic contribution [2]. Since long, it is
observed that idiopathic epilepsy has a genetic component
and its genetic etiology can be determined in a small frac-
tion of cases. Development of genome wide technologies
such as array-CGH and single-nucleotide polymorphism
genotyping enabled the detection of submicroscopic
microdeletions and microduplications also known as
CNVs [3,4]. CNVs being an important component of
human genetic variation are key players in the genetic
etiology of numerous neurodevelopmental disorders. A
number of studies have recently highlighted the role of
CNVs in the etiology of various disorders including autism
[5,6], intellectual disability (ID) [7] and schizophrenia [8,9].
Recent studies on six genomic regions showed recurrent
microdeletions on chromosomes 15q13.3, 16p13.11 and
15q11.2 and were identified as necessary genetic factors
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influencing idiopathic generalized epilepsy (IGE) [10-12].
Databases of normal and pathogenic genome variations
are available on the web and are extremely valuable tools
for interpreting CNVs identified in patients (Database of
Genomic Variants: DGV; Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl
Resources: DECIPHER). Recent studies showed that 267
different genomic loci have been associated with well
described microdeletion/microduplication syndromes
(MMSs) [13]; these informations are constantly updated.
In this study, we hypothesized that epilepsy could be
caused by CNVs and that genes within those CNVs would
be novel candidate genes for epilepsy. We selected a
cohort of 22 patients with different types of epilepsies and
performed high density whole genome array-CGH which
showed novel CNVs/genes deletion and duplication that
might be the contributory factors in the genetic etiology of
epilepsy.
Results and discussion
Array-CGH results showed gains as well as losses in differ-
ent genomic regions of 19 epilepsy patients from a cohort
of 22 epilepsy patients. But, we reported the results of only
8 patients satisfying the cut off value of duplications and
deletions (0.8 for duplication and -1.0 for deletion). Micro-
duplication of 6p12.1 was observed in five patients includ-
ing two from the same family and microdeletion of 7q32.3
in three patients was also found. These CNV findings
were confirmed by qPCR.
Detection of 6p12.1 microduplications
Whole genome 2x 400K oligonucleotide based microarray
analysis showed 99.9kb duplication at cytoband 6p12.1.
Figure 2 presented 5 horizontal red lines of 5 patients with
duplicated regions; each red line is marked with each
patients ID along with the duplicated region of that specific
patient. Out of these 5 patients, 2 were members of the
same family whereas the rest of 3 were sporadic cases. No
deletion or duplication was observed in father: 05, normal
daughter: 1192 and normal son: 1191 (Figure 1). In affected
mother: 1190, a microduplication of 51.6kb (55722611-
55774293) and in affected daughter: 1193, a microduplica-
tion of 55.8kb (55718462-55774293) was observed. Rest of
3 sporadic cases also showed duplications of different sizes
such as 241 showed a duplication of 95.6kb (55678636-
55774293); 494 showed a duplication of 82.5kb (55691753-
55774293) and 440 showed a duplication of 51.7kb
(55726917-55778628). The gene that was observed in the
duplicated region of all the patients is BMP5 (Table 1 and
Figure 2); determined by UCSC Genome Browser (http://
genome.ucsc.edu/) and Database of Genomic Variants
(http://dgv.tcag.ca/dgv/app/home). BMP5 is a member of
BMP family which belongs to transforming growth factor-
b (TGFb) superfamily. It is expressed in hippocampus,
cerebellum and striatum [14,15]. Studies also showed its
expression in developing rat superior cervical ganglion cor-
responding to initial extension of primary dendrites and in
early postnatal period during maximal dendritic growth.
Immunofluorescence analysis of cultured superior cervical
ganglion cells detected Bmp5 all over cell body of glial [16].
It was also observed that cell proliferation was reduced by
BMP5 through cell death into the progenitor cells specifi-
cally in ventral forebrain. Insertion of BMP5 in developing
chicken prosencephalon causes loss of ventral forebrain
secondary to immense cell death localized to that region.
Experimental embryos showed a loss of basal telencepha-
lon due to implantation of beads soaked in recombinant
BMP5 or BMP4 into neural tube of chicken forebrain that
resulted in holoprosencephaly (a single cerebral hemi-
sphere), cyclopia (a single midline eye) and loss of ventral
midline structures [17]. Noradrenergic (NA) neurons are
critical modulators of brain functions and have been impli-
cated in common CNS disorders [18]. Locus coeruleus
(LC), the major NA nucleus providing the main source of
noradrenaline in the brain is formed in rostral hindbrain
during embryogenesis. LC development requires either
Bmp5 or Bmp7 and one is able to compensate the loss of
the other. Also, the position of mid-hindbrain organizer
determines the size of LC and propose that Bmp5/7 play
an important role in mediating this organizer function [19].
Studies also uncovered novel roles of BMP signaling during
development of heart, allantois, branchial arches, somites
and forebrain development. Bmp5 do not appear to be
involved in establishing pattern in these tissues but neces-
sary for proliferation and maintenance of specific cell
populations [20]. Observed duplications in all patients with
reference to controls were confirmed by qPCR which
showed a significant fold increase in all patients compared
to controls Figure 3).
Detection of 7q32.3 microdeletions
Whole genome 2x 400K oligonucleotide based microarray
analysis showed 63.9kb microdeletion at cytoband 7q32.3.
Figure 4 showed 3 horizontal green lines of 3 patients with
deleted regions; each green line is marked with each
patients ID along with the deleted region of that specific
patient. In patient 1090, a microdeletion of 63.9kb
(130860344-130924315); in 1186, a microdeletion of
59.5kb (130864738-130924315) and in 495, a deletion of
56.6kb (130864738-130921416) was observed. The gene
that was observed in the deleted regions of all the patients
was PODXL (Table 1 and Figure 4); determined by UCSC
Genome Browser (http://genome.ucsc.edu/) and Database
of Genomic Variants (http://dgv.tcag.ca/dgv/app/home).
Podocalyxin (PODXL) is type-1 membrane mucin protein
belongs to CD34 family expressed abundantly in kidney
epithelial cells (podocytes) [21]; its expression has also
reported in the brain with maximum level in cortical plate,
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hippocampus, cerebellum and basal forebrain nuclei
[22,23]. In humans, it is also linked with malignant pro-
gression of brain astrocytic tumors [24]. Studies also
showed that ventricles of Podxl−/− mice were enlarged
in coronal and horizontal brain MR images which were
also confirmed through histological analysis of paraffin
embedded brain [25]. Reason of this could be either an
enhanced formation or reduced disposal of cerebrosp-
inal fluid (CSF) or it might be due to a combination of
both mechanisms. Enhanced volume of CSF might be
the result of a new steady state equilibrium of choroid
plexuses ion membrane transporters; Na+-K+ATPase, K
+ channels and Na+-2Cl−-K+ co-transporters expressed
in apical membrane and Cl−-HCO3 exchangers, a vari-
ety of Na+ coupled HCO3− transporters and K+-Cl−
cotransporters expressed in the basolateral membrane
[26]. Further analysis is required to check the involve-
ment of these ion transporters toward ventricles enlar-
gement in the absence of PODXL. Numerous human
pathological disorders are linked with enlarged ventri-
cles such as trauma, autism, bardet-biedl syndrome and
alzheimer disease [27-29]. However, an earlier and pos-
sibly best human pathological condition studied was
schizophrenia [30]. Finding of enlarged ventricles in the
patients having first schizophrenia episode has raised
the question of whether this neurodegenerative disease
exhibited at the time of symptom onset or it is consid-
ered as a neurodevelopmental process which produces
abnormal brain volumes at an early age [31]. Observed
deletions in all the patients with reference to controls
were confirmed by qPCR which showed a significant
fold decrease in all the patients compared to controls
(Figure 5).
Figure 1 Pedigree of the epilepsy family; 05: normal father; 1190:
affected mother; 1191: normal son: 1192: normal daughter: 1193:
affected daughter.
Figure 2 Summary of genome wide gains in five patients. Whole genome 2x 400K oligonucleotide based microarray analysis showing 99.9kb
duplication at cytoband 6p12.1. Five horizontal red lines showing duplicated regions of five patients; each red line is marked with each patients
ID along with the duplicated region: 1193; 55718462-55774293, 241; 55678636-55774293, 1190; 55722611-55774293, 494; 55691753-55774293 and
440; 55726917-55778628. The gene predicted in the duplicated region is BMP5.
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Conclusion
CNVs are major contributory factors in developing the
neurological disorders and also contribute in the genetic
etiology of epilepsy. In this study, we described, for the first
time, some of the novel CNVs/genes implicated in epilepsy
in the Saudi population. Our findings present a better
description of genetic variations in epilepsy, and could pro-
vide a foundation for the understanding of the critical
regions of the genome which might be involved in the
development of epilepsy. More comprehensive descriptions
of patients and identification of possible causative CNVs
and genes in the CNV regions will be required to identify
new syndromes and improve the diagnoses of epilepsy.
Methods
Patients and families
22 patients were selected with primary diagnosis of dif-
ferent types of epilepsies including epilepsy (Epi), epi-
lepsy plus mental retardation (Epi+MR) and juvenile
myoclonic epilepsy (JME) shown in the Table 1. Details
of all patients are as follows; Case 1190 and 1193: 1193
is a 4 years old female proband; her seizures were
started at the age of 3 years. Her 33 years old mother
1190 had a consanguineous marriage and also suffering
with seizures that were started at the age of 17 years.
05: father; 1192: sister and 1191: brother of the proband
were normal and no CNV was found in any of these
normal members of the family. One patient of the same
family was died at the age of 5 years due to seizures
(Figure 1). Case 440: She is 39 years old female patient
of JME and her seizures were started the age of 16
years. Case 241: He is 14 years old male patient of JME
and his seizures were started the age of 15 years. Case
1090: she is 15 years old female patient of epilepsy, her
parents had a consanguineous marriage and both are
normal. Blood samples of her parents, one normal sister
and one normal brother was not available. Her seizures
were started when she was 8 years old. Case 1186: He is
27 years old male patient of JME and his seizures were
started the age of 16 years. Case 495: She is 13 years old
Table 1 Characteristics of study participants carrying copy number variations (duplications and deletions)
Case No Sex Location CNVs Change Genes IGE Syndrome
Start (bp)-Stop (bp) Size (kb)
1193 F 6p12.1 55718462-55774293 55.8 Duplication BMP5 Epi
241 M 6p12.1 55678636-55774293 95.6 Duplication BMP5 Epi
1190 F 6p12.1 55722611-55774293 51.6 Duplication BMP5 Epi
494 M 6p12.1 55691753-55774293 82.5 Duplication BMP5 Epi+MR
440 F 6p12.1 55726917-55778628 51.7 Duplication BMP5 JME
1090 F 7q32.3 130860344-130924315 63.9 Deletion PODXL Epi
1186 M 7q32.3 130864738-130924315 59.5 Deletion PODXL JME
495 F 7q32.3 130864738-130921416 56.6 Deletion PODXL Epi+MR
Table legend text: M: Male; F: Female; CNVs: Copy number variations; bp: base pairs; kb: kilobases; BMP5: Bone morphogenetic protein-5; PODXL: Podocalyxin-like
protein; IGE: Idiopathic generalized epilepsy; Epi: Epilepsy; JME: Juvenile myoclonic epilepsy; Epi+MR: Epilepsy plus mental retardation.
Figure 3 Confirmation of CNVs by qPCR. (A) The results showed BMP5 copy number amplifications in two patients; mother (1190) and the
proband (1193) but not in healthy individuals. (B) BMP5 copy number amplifications were observed in three patients (241, 440 and 494) but not
in healthy individuals.
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female patient of epilepsy plus mental retarded. Her sei-
zures were started at the age of 6 years. Case 494: He is
7 years old male patient of epilepsy plus mental
retarded. His seizures were started the age of 3 years.
DNA preparation
Blood samples from all the patients were taken at King
Abdulaziz University Hospital with their informed con-
sent after the approval of ethical committee. DNA was
extracted by using QIAamp DNA blood mini kit (http://
www.Qiagen.com) and was quantified by NanoDrop
ND-10000 Spectrophotometer.
Array-CGH analysis
Array-CGH analysis was done by Agilent sure print G3
Hmn CGH 2x 400K arrays (Agilent Technologies, Santa
Clara, USA) following manufacturer protocol. Briefly,
500ng patient’s DNA and also reference DNA of the
same sex (Promega, Madison, USA) were digested with
RsaI (Promega, Madison, USA) and AluI (Promega,
Madison, USA) for 2hrs at 37ºC. Furthermore, these sam-
ples were labeled by random primers through Agilent
labeling kit (Agilent Technologies, Santa Clara, USA) fol-
lowing manufacturer guidelines. Patient’s DNA was
labeled with Cy5-dUTP whereas reference DNA was
labelled with Cy3-dUTP. Labeled products were purified
by Microcon YM-30 filter units (Millipore, Billerica,
USA). Patient and reference DNAs were mixed with
Cot-1 DNA (Invitrogen, USA) blocking agent and hybri-
dization buffer following by Agilent instructions. After
denaturation at 95ºC and pre-annealing at 37ºC, hybridi-
zation was done at 65ºC for 40hrs. After the two washing
Figure 4 Summary of genome wide losses in three patients. Whole genome 2x 400K oligonucleotide based microarray analysis showing 63.9kb
deletion at cytoband 7q32.3. Three horizontal green lines showing deleted regions of three patients; each green line is marked with each
patients ID along with the deleted region: 1090; 130860344-130924315, 1186; 130864738-130924315 and 495; 130864738-130921416. The gene
which is observed in the deleted region is PODXL.
Figure 5 Confirmation of CNVs by qPCR. The results showed PODXL
copy number deletions in three patients (1090, 495 and 1186) but
not in healthy individuals.
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steps, array was analyzed through Agilent Scanner
(G2505C) and Feature Extraction Software (V.1.5.1.0).
Data was analyzed by using Partek Genomics Suite Soft-
ware, Cytogenomics Software (V.2.0.6.0; Agilent Tech-
nologies, USA) and publicly available DGV.
Validation of CNVs by real-time quantitative PCR
The microdeletions and microduplications were con-
firmed by real-time quantitative PCR (qPCR). Targeted
sequences were chosen for qPCR by using Primer-3
Software (V.0.4.0). Two pair of primers were selected
for each of genomic region of two target genes; bone
morphogenetic protein-5 (BMP5) and podocalyxin-like
protein (PODXL); an endogenous gene b2-microglobulin
(B2M) and control samples. PCR was done in 10μl reac-
tion volume comprising of 05μl SYBR-Green qPCR mas-
ter mix (KAPA Biosystems, USA), 10 pmol forward and
reverse primers and 20ng genomic DNA. Reaction
cycling conditions were as follows; denaturation at 95°C
for 10minutes, annealing at 60°C for 1minute, holding
stage at 60°C for 30seconds followed by 45 cycles at
60°C for 15seconds. Each run of 96 well plate included
control samples, target genes, reference gene and non-
template control for each gene. Plate was analyzed with
StepOnePlus™ Real-Time PCR Systems (StepOnePlus™
Real-Time PCR, Applied Biosystems, Canada) raw data
was acquired using Light Cycler 480 Software. Ct is the
threshold cycle defined as the mean cycle at which the
fluorescence curve reaches an arbitrary threshold; ΔCt is
the difference between the Ct of the target gene and
that of reference gene; ΔΔCt is ΔCt value of patients
obtained by dividing the patient ΔCt value with ΔCt
value of control sample. T-test with significant P-value
<0.05 was used to find out statistical significance of pre-
dicted copy number alterations.
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